Imeglimin (Twymeeg) and Mitochondrial Dysfunction in Type 2 Diabetes: How a New Drug Class Targets Cellular Energy Failure

Why Is Mitochondrial Dysfunction Central to Type 2 Diabetes Pathology?

Mitochondria generate the ATP required for glucose-stimulated insulin secretion in pancreatic beta cells. When mitochondrial oxidative phosphorylation becomes impaired — through lipotoxicity, chronic hyperglycemia, or age-related decline — beta cells lose their ability to sense and respond to rising blood glucose levels. Simultaneously, skeletal muscle and hepatic cells with dysfunctional mitochondria exhibit reduced glucose oxidation and increased reliance on lipid metabolism, worsening insulin resistance. Research published in Diabetologia has established that individuals with type 2 diabetes consistently show reduced mitochondrial density and impaired oxidative capacity in skeletal muscle biopsies compared to matched controls.

Imeglimin was specifically designed to intervene at this bioenergetic level. By partially modulating complex I of the electron transport chain, it reduces excessive reactive oxygen species (ROS) production — a major source of oxidative damage in diabetic tissues — while preserving sufficient electron flow to maintain ATP synthesis. Critically, imeglimin also activates the nicotinamide phosphoribosyltransferase (NAMPT)-mediated NAD+ salvage pathway, replenishing the NAD+ pool that is essential for sirtuin-dependent metabolic regulation and mitochondrial biogenesis. This dual mechanism distinguishes imeglimin from metformin, which inhibits complex I more aggressively and does not directly enhance NAD+ recycling. The result is improved mitochondrial function across multiple tissue types relevant to glucose homeostasis.

What Did the TIMES Clinical Trial Program Reveal About Imeglimin's Safety and Efficacy?

The TIMES (Trials of IMeglimin for Efficacy and Safety) program comprised three sequential studies. TIMES-1, a 24-week placebo-controlled monotherapy trial published in Diabetes Care (2021), enrolled 213 Japanese adults with type 2 diabetes and demonstrated a placebo-adjusted HbA1c reduction of 0.56 percentage points with imeglimin 1000 mg twice daily. Fasting plasma glucose also declined significantly. TIMES-2 evaluated long-term safety over 52 weeks as add-on therapy to a range of existing antidiabetic agents — including DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, sulfonylureas, and insulin — finding that imeglimin provided additional glycemic benefit without unexpected safety signals across all combinations.

TIMES-3 specifically assessed the combination of imeglimin with insulin therapy over 16 weeks, demonstrating additive glucose-lowering effects without increasing hypoglycemia risk. Across all three trials, the most commonly reported adverse events were gastrointestinal symptoms (nausea, diarrhea), but these occurred at rates notably lower than those typically seen with metformin initiation. No cases of lactic acidosis were reported, consistent with imeglimin's more selective modulation of complex I compared to the broader inhibition produced by biguanides at high doses. These findings supported the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) approval of Twymeeg in June 2021, making Japan the first country to approve a glimide-class medication.

How Does Imeglimin Protect Pancreatic Beta Cells from Progressive Decline?

Progressive beta-cell failure is a hallmark of type 2 diabetes, driven by glucotoxicity, lipotoxicity, and chronic oxidative stress within the islets of Langerhans. Most current therapies — including sulfonylureas and insulin — manage the consequences of beta-cell decline without addressing its cellular mechanisms. Preclinical work by Hallakou-Bozec and colleagues, published in Diabetes, Obesity and Metabolism (2021), demonstrated that imeglimin reduced mitochondrial permeability transition pore opening in beta cells exposed to pro-apoptotic stimuli, a key step in the programmed cell death cascade triggered by oxidative damage.

Furthermore, imeglimin enhanced glucose-stimulated insulin secretion in isolated human and rodent islets without increasing basal insulin release — an important distinction from sulfonylureas, which stimulate insulin release regardless of ambient glucose levels and thereby increase hypoglycemia risk. The preservation of glucose-dependent secretion dynamics suggests that imeglimin supports physiological beta-cell function rather than exhausting secretory reserves. While long-term clinical data confirming durable beta-cell preservation in humans are still needed, the mechanistic rationale and preclinical findings position imeglimin as a potentially disease-modifying agent — a category in which no currently approved diabetes drug has established definitive evidence.